5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Sell
32
BCYC Quote, Financials, Valuation and Earnings
Last price:
$8.20
Seasonality move
:
10.67%
Day range:
$7.39 - $8.04
52-week range:
$6.10 - $28.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.61x
P/B ratio:
0.73x
Volume:
659.9K
Avg. volume:
420K
1-year change:
-66.29%
Market cap:
$538.8M
Revenue:
$35.3M
EPS (TTM):
-$3.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$8.7M | -$0.81 | 0.73% | -22.39% | $26.27 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
AUTL
Autolus Therapeutics PLC
|
$2M | -$0.25 | -84.24% | -7.08% | $10.01 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$54.8M | -$0.03 | -- | -99.24% | $94.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$7.78 | $26.27 | $538.8M | -- | $0.00 | 0% | 19.61x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.30 | $1.71 | $77.2M | -- | $0.00 | 0% | 0.43x |
|
AUTL
Autolus Therapeutics PLC
|
$1.23 | $10.01 | $327.3M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.38 | $17.94 | $3.5M | -- | $0.00 | 0% | 1.44x |
|
NCNA
NuCana PLC
|
$0.30 | $104.00 | $1.8M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$69.14 | $94.10 | $5.9B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.409 | -- | 14.57x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 3.631 | 36.44% | 2.60x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 1.803 | -- | 10.47x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.357 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | -0.390 | -- | -- |
|
VRNA
Verona Pharma PLC
|
51.62% | 0.242 | 4.47% | 8.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$70M | -27.79% | -28.27% | -619.32% | -$87M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$75.9M | -51.91% | -51.91% | -196479.31% | -$61.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$72.8M | -$10.3M | -51.07% | -85.84% | -8.34% | -$12.1M |
Bicycle Therapeutics PLC vs. Competitors
-
Which has Higher Returns BCYC or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of -2303.38%. Bicycle Therapeutics PLC's return on equity of -28.27% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About BCYC or ADAP?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 237.7%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 468.75%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 ADAPAdaptimmune Therapeutics PLC2 3 0 -
Is BCYC or ADAP More Risky?
Bicycle Therapeutics PLC has a beta of 1.599, which suggesting that the stock is 59.85% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.
-
Which is a Better Dividend Stock BCYC or ADAP?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or ADAP?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Bicycle Therapeutics PLC's net income of -$60.8M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 19.61x versus 0.43x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC19.61x -- $10M -$60.8M ADAPAdaptimmune Therapeutics PLC0.43x -- $3.2M -$74.2M
-
Which has Higher Returns BCYC or AUTL?
Autolus Therapeutics PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of -95193.1%. Bicycle Therapeutics PLC's return on equity of -28.27% beat Autolus Therapeutics PLC's return on equity of -51.91%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M AUTLAutolus Therapeutics PLC-- -$0.09 $427.3M -
What do Analysts Say About BCYC or AUTL?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 237.7%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.01 which suggests that it could grow by 713.91%. Given that Autolus Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is BCYC or AUTL More Risky?
Bicycle Therapeutics PLC has a beta of 1.599, which suggesting that the stock is 59.85% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.723%.
-
Which is a Better Dividend Stock BCYC or AUTL?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or AUTL?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than Autolus Therapeutics PLC quarterly revenues of $29K. Bicycle Therapeutics PLC's net income of -$60.8M is lower than Autolus Therapeutics PLC's net income of -$27.6M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 19.61x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC19.61x -- $10M -$60.8M AUTLAutolus Therapeutics PLC-- -- $29K -$27.6M
-
Which has Higher Returns BCYC or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -28.27% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About BCYC or BDRX?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 237.7%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1200.28%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is BCYC or BDRX More Risky?
Bicycle Therapeutics PLC has a beta of 1.599, which suggesting that the stock is 59.85% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.
-
Which is a Better Dividend Stock BCYC or BDRX?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or BDRX?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$60.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 19.61x versus 1.44x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC19.61x -- $10M -$60.8M BDRXBiodexa Pharmaceuticals PLC1.44x -- -- --
-
Which has Higher Returns BCYC or NCNA?
NuCana PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -28.27% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About BCYC or NCNA?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 237.7%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 34440.02%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 NCNANuCana PLC0 1 0 -
Is BCYC or NCNA More Risky?
Bicycle Therapeutics PLC has a beta of 1.599, which suggesting that the stock is 59.85% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.
-
Which is a Better Dividend Stock BCYC or NCNA?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or NCNA?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than NuCana PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$60.8M is lower than NuCana PLC's net income of -$836.1K. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 19.61x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC19.61x -- $10M -$60.8M NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns BCYC or VRNA?
Verona Pharma PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of -21.4%. Bicycle Therapeutics PLC's return on equity of -28.27% beat Verona Pharma PLC's return on equity of -85.84%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M VRNAVerona Pharma PLC95.53% -$0.16 $468.3M -
What do Analysts Say About BCYC or VRNA?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 237.7%. On the other hand Verona Pharma PLC has an analysts' consensus of $94.10 which suggests that it could grow by 36.1%. Given that Bicycle Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 VRNAVerona Pharma PLC7 0 0 -
Is BCYC or VRNA More Risky?
Bicycle Therapeutics PLC has a beta of 1.599, which suggesting that the stock is 59.85% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.206, suggesting its less volatile than the S&P 500 by 79.434%.
-
Which is a Better Dividend Stock BCYC or VRNA?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or VRNA?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are smaller than Verona Pharma PLC quarterly revenues of $76.3M. Bicycle Therapeutics PLC's net income of -$60.8M is lower than Verona Pharma PLC's net income of -$16.3M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 19.61x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC19.61x -- $10M -$60.8M VRNAVerona Pharma PLC-- -- $76.3M -$16.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
